But, the idea is still controversial, and a large, nationwide trial of older adults, slated to test the hypothesis, hasn't started yet.
It also points to the need for better strategies to make these treatments more accessible and available to those who need them. Prior to this research, a small study of 106 postmenopausal women published in 2024 in the medical journal Menopause found that those who were on both MHT and the GLP-1 drug semaglutide had lost about 16 percent of their total body weight after a year, compared to 12 percent for women on a GLP-1 alone
Syringe listings include those details because they describe different parts of the product
Experts agree removing GLP-1s from the 503B bulks list will significantly lower the availability of compounded GLP-1s drugs
Mazer CD, Hare GM, Connelly PW, Gilbert RE, Shehata N, Quan A, et al
[1] [2] Whether hair loss occurred at a low frequency or was not captured as a discrete outcome in the published data is not entirely clear from the available report